Clinical trials: Medicine Regimen
Postoperative Pain
A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-183)
The purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of pain following dental surgery.
- Trial name
- NCT00092326
- Testing
- MK0966, rofecoxib
- Volunteers
- 269 people
- Sponsor
- Merck Sharp & Dohme LLC
Multidrug Resistant Tuberculosis
A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)
The purpose of this trial is to assess the safety, tolerability, pharmacokinetics, and efficacy of long-term (6-month) treatment with delamanid plus an optimized background regimen (OBR) of other anti-tuberculosis drugs in…
- Trial name
- NCT01859923
- Testing
- Delamanid, Delamanid Pediatric Formulation (DPF), Optimized Background Regimen (OBR)
- Where
- 3 sites in Philippines, South Africa
- Volunteers
- 37 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Psoriasis
An Observational Monocentric Study Investigating the Association Between Trough Serum Levels of Etanercept, Antibodies Towards Etanercept and Its Effectiveness in Psoriasis Patients
The purpose of this study is to investigate the association between trough serum levels of etanercept, antibodies towards etanercept and its effectiveness in psoriasis patients.
- Trial name
- DERM (NCT02322580)
- Testing
- etanercept
- Volunteers
- 56 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
HIV Infections
A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy
This phase 2b study is designed to assess the long-term efficacy (24 weeks) of MPC-4326 in combination with a 2-3 drug optimized background regimen (OBR) relative to the efficacy of a 3-4 antiretroviral (ARV) regimen in treatment…
- Trial name
- NCT01026727
- Testing
- MPC-4326 plus a 2-3 drug optimized background regimen (OBR), 3-4 commercially available antiretroviral drugs
- Where
- 25 sites in United States, Canada
- Volunteers
- 2 people
- Sponsor
- Myrexis Inc.
Diffuse Large B Cell Lymphoma
Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma
A single-center, open, single-arm clinical study of the efficacy and safety of a novel targeted agent in combination with R-ICE in the treatment of relapsed and refractory diffuse Large B-cell lymphoma.
- Trial name
- R-ICE+X (NCT05348213)
- Testing
- Zanubrutinib plus R-ICE, Decitabine plus R-ICE, Chidamide plus R-ICE
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Ruijin Hospital
de Novo Kidney Transplant Recipients, Renal Transplantation
Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids.
This study will compare the following immunosuppressive regimens in recipients of kidney transplantation: A) everolimus, cyclosporine and steroids given once-a-day; B) everolimus and cyclosporine given twice a day with steroid…
- Trial name
- EVIDENCE (NCT01023815)
- Testing
- everolimus, cyclosporine, Prednison (continuous steroids)
- Where
- 28 sites in Italy
- Volunteers
- 330 people
- Sponsor
- Novartis
HCC - Hepatocellular Carcinoma
Treatment Selection by 3D Bioprinting Liver Model to Prevent Liver Cancer Recurrence
This study is a feasibility study about a test on adjuvant therapy for patients in hepatocellular carcinoma (HCC) with a higher risk of tumour recurrence after liver resection or ablation.
- Trial name
- NCT07839767
- Testing
- Liver-in-cube testing
- Where
- Hong Kong
- Volunteers
- 20 people
- Sponsor
- The University of Hong Kong
Acquired Immunodeficiency Syndrome, HIV Infections
Once-Daily Drug Regimen for HIV-Infected Patients
This study will examine the safety of giving antiviral therapy for HIV infection in a once-daily dosing schedule, and assess how well patients tolerate this regimen.
- Trial name
- NCT00001968
- Testing
- Amprenavir, Ritonavir, Abacavir
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Cancer
Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003585
- Testing
- aldesleukin, recombinant interferon alfa, fluorouracil
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of New Mexico
De Novo Renal Transplant Recipient.
Fixed Dose MMF vs Concentration Controlled MMF After Renal Transplantation
Determine the value of a clinically feasible strategy of therapeutic drug monitoring compared with fixed dosing in de novo MMF treated renal transplant recipients with respect to the incidence of treatment failure.
- Trial name
- NCT00166244
- Testing
- Mycophenolate Mofetil
- Where
- 67 sites in Australia, Austria and 17 more
- Volunteers
- 901 people
- Sponsor
- Erasmus Medical Center
HIV
Emtricitabine/Tenofovir Alafenamide as Salvage ART
Background: HIV attacks the immune system. Antiretroviral therapy (ART) is a combination of drugs used for treating HIV infection. For some people, ART drugs stop working against their HIV.
- Trial name
- NCT02556333
- Testing
- FTC/TAF
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Invasive Candidiasis
A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)
Comparison of the safety and effectiveness of standard drug dosing versus a daily dose 3 times higher than the standard dose in patients with invasive candidiasis (bloodstream and/or systemic yeast infections)
- Trial name
- NCT00250432
- Testing
- caspofungin acetate
- Volunteers
- 204 people
- Sponsor
- Merck Sharp & Dohme LLC
Tuberculosis, Multidrug-Resistant
Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (explores what the body does to the drug), and anti-mycobacterial activity of bedaquiline (TMC207) in children and adolescents (0 months to less…
- Trial name
- NCT02354014
- Testing
- Bedaquiline (TMC207), Background Regimen (BR)
- Where
- 11 sites in Mozambique, Philippines and 4 more
- Volunteers
- 60 people
- Sponsor
- Janssen Research & Development, LLC
Pulmonary Tuberculosis
AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT
Tuberculosis (TB) kills 1.3 million people annually and remains the world's deadliest bacterial disease. The standard four-drug RIPE regimen achieves only 85% cure rates and causes drug-induced hepatotoxicity in 25-37% of…
- Trial name
- AIPH-TB-RCT-P2 (NCT07467252)
- Testing
- Pyrazinamide and Hydroxychloroquine (AI-Optimised), Standard RIPE Regimen (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol)
- Where
- Saudi Arabia
- Volunteers
- 200 people
- Sponsor
- Ministry of Health, Saudi Arabia
Diabetes Mellitus
Medication Regimen Complexity and Glycemic Control in Patients With Diabetes
Polypharmacy is an alarming health issue that is defined as prescription of multiple medications, of which some are redundant or unnecessary. Due to comorbidities, diabetic patients are often prescribed multiple medications.
- Trial name
- NCT03324971
- Testing
- Medications review
- Where
- Egypt
- Volunteers
- 78 people
- Sponsor
- Kasr El Aini Hospital
Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
Background: Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT06694454
- Testing
- azacytidine, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Constipation, Bowel Dysfunction
Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication
A multicenter study to evaluate the effectiveness and safety of multiple dosage regimens of an investigational drug for the treatment of constipation due to prescription pain medication in subjects with cancer pain.
- Trial name
- NCT00101998
- Testing
- alvimopan
- Where
- 162 sites in United States, Argentina and 24 more
- Volunteers
- 233 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Tuberculosis, Tuberculosis, Pulmonary
Shortened Regimen for Drug-susceptible TB in Children
While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of more powerful drugs.
- Conditions
- Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph Node, Mycobacterium Tuberculosis
- Trial name
- SMILE-TB (NCT06253715)
- Testing
- Isoniazid, Rifampin, Pyrazinamide
- Where
- 9 sites in India, Indonesia and 5 more
- Volunteers
- 860 people
- Sponsor
- Johns Hopkins University
HIV
A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence
PRO 140 2102 is a phase 2b, national, multicenter, randomized, double-blind, placebo-controlled study in order to evaluate the safety and efficacy of PRO 140 (anti-CCR5 monoclonal antibody) administered subcutaneously as an…
- Trial name
- NCT01272258
- Testing
- PRO 140
- Where
- United States
- Sponsor
- CytoDyn, Inc.
HIV Infections
A Multicenter Phase II Double-Blind Exploratory Study to Evaluate Differences Among Various Zidovudine/Didanosine Regimens on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection
To determine the relative antiviral activity and safety of zidovudine ( AZT ) and didanosine ( ddI ) alone and in combination, as well as in various sequences of administration.
- Trial name
- NCT00000823
- Testing
- Zidovudine, Didanosine
- Where
- 22 sites in United States
- Volunteers
- 85 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)